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Increasing and Worsening Late Effects in Childhood Cancer 
Survivors during Follow-up
Recent advances in childhood cancer treatment have increased survival rates to 80%. Two 
out of three survivors experience late effects (LEs). From a group of 241 survivors previously 
described, 193 were followed at the long-term follow-up clinic (LTFC) of Severance 
Hospital in Korea; the presence of LEs was confirmed by oncologists. We reported the 
change in LEs during 3 yr of follow-up. The median follow-up from diagnosis was 10.4 yr 
(5.1-26.2 yr). Among 193 survivors, the percentage of patients with at least one LE 
increased from 63.2% at the initial visit to 75.1% at the most recent visit (P = 0.011). The 
proportion of patients having multiple LEs and grade 2 or higher LEs increased from the 
initial visit (P = 0.001 respectively). Forty-eight non-responders to the LTFC were older and 
had less frequent and severe LEs than responders at initial visit (all P < 0.05). In multivariate 
analysis, younger age at diagnosis, older age at initial visit, a diagnosis of a brain tumor or 
lymphoma, and use of radiotherapy were significant risk factors for LEs (all P < 0.05). 
Adverse changes in LEs were seen among the survivors, regardless of most clinical risk 
factors. They need to receive comprehensive, long-term follow up.
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INTRODUCTION
Recent advances in the diagnosis, treatment, and supportive 
care of childhood cancers have increased the survival rate up to 
80% (1). As more survivors of childhood cancers reach adult-
hood, chronic toxic effects from treatment−the so called “late 
effects (LEs)”−are also increasing in frequency (2, 3). In the 
United States, there are about 270,000 survivors of childhood 
cancers, and about one of every 640 young adults (20-39 yr of 
age) is a childhood cancer survivor. In general, two out of three 
of survivors experience at least one late effect (2).
 The range of LEs is quite broad and can involve endocrine 
(including gonadal and growth), cardiovascular, pulmonary, 
and renal systems, or result in neurocognitive abnormalities (4, 
5). Increasing concerns about chronic health conditions and 
health status, including quality of life, have prompted a call for 
guidelines for long-term follow-up of survivors of childhood 
cancers in various regions of the world, and multidisciplinary 
approach is being performed (6, 7).
 There are many published reports on LEs and health status 
(i.e., general and mental health status). While most of the stud-
ies were focused on a single LE or a single disease entity, some 
large scale studies on overall health status were recently con-
ducted in Western countries (2, 8-10). Due to the large number 
of childhood cancer survivors, many studies have used public 
health data or questionnaires instead of confirming LEs by phy-
sicians.
 We have previously published a report on the overall health 
conditions of childhood cancer survivors seen at a long-term 
follow-up clinic (LTFC), the first one to be established in Korea 
(11). Here we report the follow-up data for these survivors. The 
purpose of this study was to determine the characteristic chang-
es in LEs in the same cohort of survivors and to present insights 
for development of well-coordinated, follow-up protocols for 
survivors.
MATERIALS AND METHODS
In January 2005, an LTFC for childhood cancer survivors was 
established in Severance Hospital, Yonsei University Health 
System (YUHS) in Seoul, Korea. A childhood cancer survivor 
was defined as a person who survived for at least 2 yr after com-
pletion of cancer therapy. Members of a society of childhood 
cancer survivors treated at Severance Hospital were invited to 
the LTFC. This study included 241 childhood cancer survivors 
who were included in our previous report on the health status 
of survivors. All patients were diagnosed before the age of 18 yr 
and were treated at Severance Hospital between 1980 and 2007. 
Other inclusion and exclusion criteria for survivor recruitment 
are described in the previous study (11). While follow-up on a 
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regular basis was recommended for all 241 survivors, only 193 
survivors were being followed at the clinic as of February 25, 
2011.
 Medical records were reviewed to determine treatment his-
tory and health risks for each survivor. Many published long-
term follow-up guidelines for the survivors were adopted and 
modified by YUHS to develop a follow-up protocol, taking into 
consideration the expertise, effectiveness, and regional reim-
bursement environments of Korea (12-14). Detailed operation 
of our LTFC is described in the previous report (11).
Data analysis 
In the previous study, late effects were defined as adverse events 
experienced by survivors at least 2 yr after completion of thera-
py. The severity of each LE was graded according to the Com-
mon Terminology Criteria for Adverse Events v3.0 (CTCAE). 
Based on other reports, the grades were considered as continu-
ous variables in order to compare the severity of LEs between 
risk groups (15, 16).
 Late effects were analyzed in three ways: the number of LEs, 
the mean severity of LEs, and the sum of LEs grades (sum). Since 
LEs were classified by both individual organs and body sys-
tems, to avoid counting an LE more than once, the number of 
LEs represents the number of affected body systems (online 
supplemental Table S1). The mean severity is the arithmetic 
mean of the severity grades. The sum of grades of LEs takes the 
sum of all LE grades in each survivor and it reflects both the 
number and severity of LEs that each survivor has.
Statistical analyses
Health conditions were compared between 48 survivors who 
were lost to follow-up (non-responders) and the 193 survivors 
(responders) who were followed. The significance of the num-
ber, mean severity, and sum of LEs was tested by chi-square 
test, Student t-test, paired t-test, and one-way analysis of vari-
ance (ANOVA). A correlation analysis (Pearson’s coefficient) 
was also conducted. Non-parametric variables were tested us-
ing the Mann-Whitney test. A multiple linear regression analy-
sis was performed to examine the association between clinical 
risk factors and the number, mean severity, or sum of LEs.
Ethics statement
This is an observational cohort study which is approved by the 
Yonsei University Health System’s institutional review roard 
(IRB, 4-2008-0268). Informed consent was waived by the board. 
RESULTS
Late effects–initial versus recent visit
For the 193 survivors (responders), the mean sum of grades at 
the most recent visit was increased compared with the initial 
visit (2.6 ± 0.2 vs 1.7 ± 0.1, respectively, P < 0.001; Table 1). Late 
effects were observed in 75.1% of responders at the recent visit, 
which was higher than at the initial visit (63.2%, P = 0.011). Five 
LEs were observed in 3.6% of responders at a recent visit, com-
pared with only one (0.5%) of all survivors at initial visit. Among 
responders, 53.3% had grade 2 or higher LEs, compared with 
26.4% at initial visit (P = 0.001). There was one death (grade 5) 
among responders, due to dilated cardiomyopathy related with 
anthracyclines.
Demographic findings of responders and non-responders
In the responder group, 62.2% were male, and 37.8% were fe-
male (online supplemental Table S2). The median age at diag-
nosis was 4.4 yr (range, 0.0-16.8 yr) for responders and 5.0 yr 
(range, 0.2-16.8 yr) for non-responders (P = 0.628). Age at initial 
visit and current age were all higher in the non-responder group 
compared with the responder group (all P = 0.001). The medi-
an time elapsed since completion of treatment was also higher 
in non-responders than in responders (P < 0.001).
 In the responder group (n = 193), 36.8% (n = 71) had leuke-
mia and 15.5% (n = 30) had lymphoma. The distribution of ma-
lignancies and treatment modalities were not significantly dif-
ferent between the two groups (P = 0.655 and P = 0.088, respec-
tively). The proportion of survivors who had undergone a he-
matopoietic stem cell transplant (HSCT) was significantly high-
er in the responder group compared with the non-responder 
group (20.7% [40/193] vs 4.2% [2/48], P = 0.007).
Overall late effects for responder and non-responder 
groups at initial visit 
The sum at the initial visit was significantly lower in non-re-
Table 1. Late effects (LEs) in childhood cancer survivors at the initial and recent visits 
Late effects
Initial visit Recent visit
P valueNo. of survivors 
(%)*
No. of survivors 
(%)†
Sum of grades 1.7 ± 0.1 2.6 ± 0.2 < 0.001
Presence of LEs
No
Yes
71 (36.8)
122 (63.2)
48 (24.9)
145 (75.1)
0.011
No. of LEs per survivor
1
2
3
4
5
71 (36.8)
30 (15.5)
13 (6.7)
7 (3.6)
1 (0.5)
48 (24.9)
56 (29.0)
25 (13.0)
9 (4.7)
7 (3.6)
< 0.001
Severity of LEs per survivor‡
Mild
Moderate
Severe
Life-threatening
Death
49 (25.4)
50 (25.9)
22 (11.4)
1 (0.5)
0 (0)
42 (21.8)
62 (32.1)
39 (20.2)
1 (0.5)
1 (0.5)
0.001
*Percentage is based on all survivors at initial visit (n = 241); †Percentage is based 
on all followed survivors at recent visit (n = 193); ‡Severity was graded based on the 
Common Terminology Criteria of Adverse Events version 3.0 (CTCAE v3.0).
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sponders than in responders (1.0 ± 0.2 vs 1.7 ± 0.1, respectively, 
P = 0.01, online supplemental Table S3). The percentage of sur-
vivors who presented with LEs was lower in non-responders 
compared with responders (45.8% vs 63.2%, respectively, P =  
0.028). Twenty-one (10.9%) survivors in the responder group 
had three or more LEs compared with only two (5.2%) survivors 
in the non-responder group (P = 0.048). A lower proportion of 
survivors (20.9%) in non-responder group had grade 2 or higher 
LEs in comparison with the responder group (37.8%, P = 0.016).
Change in late effects by body systems in responder group
The most common LEs observed at recent visit were related to 
the endocrine system (Table 2). Of all responders, 43% (83/193) 
had endocrine LEs, including thyroid (n = 42), growth (n = 33), 
sexual (n = 42), and metabolic (n = 12) effects. For grade 3 or 
higher LEs, endocrine (n = 20, 10.4%), and neurologic (n = 9) 
abnormalities were the most common at recent visit.
 In the paired analysis for findings from initial and follow-up 
visits, increases in both the percentage and the mean severity of 
specific LEs were seen for many of the body systems. Endocrine-
associated LEs increased from 31.6% to 43.0% (P = 0.021) with 
an increase in mean severity from 0.54 ± 0.06 to 0.74 ± 0.08 (P =  
0.002). Musculoskeletal-associated and neurologic LEs increas-
ed in number and severity during the follow-up. No significant 
changes in percentage or severity of LEs were observed in bone 
marrow or in cardiovascular, auditory, ocular, pulmonary, or 
renal systems.
 Among responders, two patients relapsed. One patient diag-
nosed with acute lymphoblastic leukemia at the age of 4.8 yr; 
relapsed at 10 yr. The other patient had non-Hodgkin’s lympho-
ma at 5.7 yr, and developed leukemic transformation at 10.4 yr.
 Three patients developed secondary malignancies. One pa-
tient with non-Hodgkin’s lymphoma was diagnosed with pan-
creatic neuroendocrine tumor 20.3 yr after the first cancer diag-
nosis. A patient with acute lymphoblastic leukemia developed 
glioblastoma multiforme 8.9 yr later. The last patient, with a 
malignant fibrous histiocytoma, was found to have glioblasto-
ma multiforme 8.6 yr later.
Table 2. Change in number, proportion and severity of late effects by system from initial to recent visit
Involved organ/Function
Severity of late effects Sum of 
cases
Proportion P value Mean grade P value
1 2 3 4 5 
Bone marrow 1st*
2nd†
5 
5 
1 
1 
0 
0 
1 
1 
0 
0 
7 
7 
3.6%
3.6%
1.000 0.06 ± 0.03
0.06 ± 0.03
1.000
Cardiovascular 1st
2nd
19 
11 
3 
2 
0 
2 
0 
0 
0 
1 
22 
16 
11.4%
8.3%
0.305 0.20 ± 0.04
0.20 ± 0.06
0.877
Ear 1st
2nd
4 
6 
6 
8 
5 
6 
0 
0 
0 
0 
15 
20 
7.8%
10.4%
0.375 0.78 ± 0.18
1.00 ± 0.18
0.060
Eye 1st
2nd
3 
2 
3 
5 
1 
1 
0 
0 
0 
0 
7 
8 
3.6%
4.1%
0.792 0.39 ± 0.14
0.48 ± 0.16
0.374
Gastrointestinal‡ 1st
2nd
7 
12 
2 
7 
1 
1 
0 
0 
0 
0 
10 
20 
5.2%
10.4%
0.057 0.07 ± 0.02
0.15 ± 0.03
0.022
Growth‡ 1st
2nd
11 
8 
14 
22 
1 
3 
0 
0 
0 
0 
26 
33 
13.5%
17.1%
0.322 0.23 ± 0.05
0.34 ± 0.06
0.006
Metabolic 1st
2nd
5 
12 
0 
0 
0 
0 
0 
0 
0 
0 
5 
12 
2.6%
6.2%
0.082 0.03 ± 0.01
0.07 ± 0.02
0.052
Musculoskeletal‡ 1st
2nd
15 
36 
3 
14 
1 
3 
0 
0 
0 
0 
19 
53 
9.8%
27.5%
< 0.001 0.30 ± 0.07
0.92 ± 0.09
< 0.001
Kidney 1st
2nd
6 
7 
3 
3 
3 
0 
0 
0 
0 
0 
12 
10 
6.2%
5.2%
0.661 0.11 ± 0.03
0.07 ± 0.02
0.158
Neurologic‡ 1st
2nd
4 
7 
7 
14 
5 
9 
0 
0 
0 
0 
16 
30 
8.3%
15.5%
0.028 0.32 ± 0.08
0.60 ± 0.10
< 0.001
Obesity 1st
2nd
1 
1 
19 
21 
1 
1 
0 
0 
0 
0 
21 
23 
10.9%
11.9%
0.749 0.26 ± 0.05
0.28 ± 0.06
0.158
Other endo§ 1st
2nd
2 
3 
6 
7 
0 
0 
0 
0 
0 
0 
8 
10 
4.1%
5.2%
0.629 0.29 ± 0.11
0.40 ± 0.12
0.058
Lung 1st
2nd
2 
2 
1 
2 
0 
0 
0 
0 
0 
0 
3 
4 
1.6%
2.1%
0.703 0.03 ± 0.02
0.04 ± 0.02
0.416
Sexual/Puberty‡ 1st
2nd
14 
17 
3 
8 
6 
17 
0 
0 
0 
0 
23 
42 
11.9%
21.8%
0.010 0.25 ± 0.05
0.54 ± 0.08
< 0.001
Skin‡ 1st
2nd
2 
3 
3 
9 
0 
0 
0 
0 
0 
0 
5 
12 
2.6%
6.2%
0.082 0.14 ± 0.06
0.36 ± 0.10
0.008
Thyroid‡ 1st
2nd
22 
26 
9 
16 
0 
0 
0 
0 
0 
0 
31 
42 
16.1%
21.8%
0.153 0.25 ± 0.04
0.36 ± 0.05
0.003
Endocrine‡ 1st
2nd
33 
31 
21 
32 
7 
20 
0 
0 
0 
0 
61 
83 
31.6%
43.0%
0.021 0.54 ± 0.06
0.74 ± 0.08
0.002
*Means initial visit; †Means recent visit; ‡Statistically significant in proportion of having late effects or severity; §”Other endo” includes diabetes insipidus and adrenal disorders.
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Change in the number of late effects 
The number of LEs increased in both males and females (P <  
0.001). The number of LEs increased regardless of the initial di-
agnosis, except for neuroblastoma (Table 3). All brain tumor 
survivors (n = 19) experienced LEs. The percentage of survivors 
with multiple LEs was higher among brain tumor survivors 
(52.6% to 84.2%, P < 0.001). Wilms tumor survivors experienced 
the lowest percentage of LEs (52.4% [11/21]) based on diagnosis.
 The number of LEs increased in all treatment groups (i.e., 
chemotherapy, radiotherapy, and surgery). Survivors treated 
with radiotherapy had the highest number of LEs, and this num-
ber markedly increased during follow-up (P < 0.001). 
Change in mean severity and total sum of grades during 
the follow-up
Increases were seen in the severity and the sum of LEs from ini-
tial to recent visit in both male and female survivors (Fig. 1). 
When assessed by diagnostic groups, all but Wilms tumor and 
neuroblastoma survivors showed increases in severity and sum 
of LEs. Brain tumor survivors scored the highest severity and 
sum at recent visit (2.7 ± 0.1 and 6.3 ± 0.6, respectively). In these 
patients, both the severity and sum increased during follow-up 
(P = 0.016 and P < 0.001). For Wilms tumor and neuroblasto-
ma, neither the mean severity nor sum significantly increased 
from initial to recent visit. Wilms tumor survivors also had the 
lowest mean severity and sum among diagnostic groups at re-
cent visit. 
 Mean severity and sum increased in all treatment groups. 
How ever, for HSCT survivors, the increase in mean severity from 
initial to recent visit did not reach statistical significance (P =  
0.086). Survivors treated with radiotherapy presented with the 
highest severity and sum of LEs.
Age and change in late effects 
The number, severity, and sum of LEs all increased from initial 
to recent visit in all age groups (Fig. 2): age at diagnosis (< 2, 2 - 
6 and > 6 yr), age at initial visit (> 9, 9-16, > 16 yr), and the num-
ber of yr after completion of therapy (< 5, 5-10, > 15 yr). When 
groups were compared by age at diagnosis, the number, severi-
ty, and sum of LEs were all significantly higher in the older age 
at diagnosis group (> 6 yr).
 The number of LEs at follow-up was higher in the older ‘age 
at initial visit’ group. However, there were no significant differ-
ences in severity and sum for each ‘age at initial visit’ group at 
recent LTFC visit. The number, severity, and sum of LEs at fol-
low-up were not significantly different when ‘years after com-
pletion of therapy’ groups were compared.
Multivariate analysis of change in number, severity, and 
total sum of grades
Age was not significantly associated with change in the number 
of LEs (Table 4). For diagnostic groups, both brain tumor and 
lymphoma had a significant effect on the change in number of 
LEs. Radiotherapy was the only significant treatment factor af-
Table 3. Change in number of late effects from initial to recent visit by clinical factors 
Clinical factor (N)
No. of late effects per survival (N) Survivors with  
late effects (%)*
Survivors with multiple 
late effects (%)*
No. of 
late effects
P value†
0 1 2 3 4 5
Sex Male (n = 120)
Female (n = 73)
1st
2nd
1st
2nd
45
28
26
20
41
36
30
20
23
32
7
16
7
16
6
9
3
4
4
5
1
4
0
3
75 (62.5)
92 (76.7)
47 (64.4)
53 (72.6)
34 (28.3) 
56 (46.7) 
17 (23.3) 
33 (45.2) 
1.05 ± 0.10
1.53 ± 0.12
1.07 ± 0.13
1.56 ± 0.16
< 0.001
< 0.001
Diagnosis Leukemia (n = 71)
Lymphoma (n = 30)
Brain tumor (n = 19)
WT (n = 21)
NB (n = 10)
Others (n = 42)
1st
2nd
1st
2nd
1st
2nd
1st
2nd
1st
2nd
1st
2nd
23
21
14
7
1
0
12
10
5
2
16
8
31
22
9
9
8
3
8
5
4
4
11
13
9
16
4
6
5
4
0
5
0
3
12
14
5
8
2
3
3
6
1
1
1
1
2
7
3
2
0
3
2
3
0
0
0
0
1
0
0
2
1
2
0
3
0
0
0
0
0
0
48 (67.6)
50 (70.4)
16 (53.3)
23 (76.7)
18 (94.7)
19 (100)
9 (42.9)
11 (52.4)
5 (50.0)
8 (80.0) 
26 (61.9)
34 (81.0)
17 (23.9) 
28 (39.4) 
7 (23.3) 
14 (46.7) 
10 (52.6) 
16 (84.2) 
1 (4.8) 
6 (28.6) 
1 (10.0) 
4 (40.0) 
15 (35.7) 
21 (50.0) 
1.07 ± 0.13
1.35 ± 0.15
0.93 ± 0.22
1.73 ± 0.28
1.84 ± 0.26
2.95 ± 0.30
0.52 ± 0.16
0.86 ± 0.21
0.80 ± 0.39
1.40 ± 0.37
1.07 ± 0.16
1.48 ± 0.15
0.003
0.002
< 0.001
0.049
0.081
0.005
Chemotherapy (n = 189) 1st
2nd
67
46
71
54
30
48
13
25
7
9
1
7
122 (64.6)
143 (75.7)
51 (27.0) 
89 (47.1) 
1.07 ± 0.08
1.57 ± 0.96
< 0.001
HSCT (n = 40) 1st
2nd
6
5
16
14
10
8
5
5
3
5
0
1
34 (85.0)
33 (82.5)
18 (45.0) 
19 (47.5) 
1.58 ± 0.18
1.93 ± 0.22
0.042
Radiotherapy (n = 75) 1st
2nd
17
4
24
15
16
24
11
18
7
9
0
5
58 (77.3)
71 (94.7)
34 (45.3) 
56 (74.7) 
1.56 ± 0.14
2.37 ± 0.15
< 0.001
Surgery (n = 80) 1st
2nd
33
20
23
19
13
23
6
9
4
5
1
4
47 (58.8)
60 (75.0)
24 (30.0) 
41 (51.3) 
1.10 ± 0.14
1.65 ± 0.16
< 0.001
*Percent is based on the total number of survivors with a specific clinical risk factor; †Paired t-test. GI, gastrointestinal; HSCT, hematopoietic stem cell transplantation; NB, neu-
roblastoma; WT, Wilms tumor. 
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fecting the change of number of LEs (P = 0.001) as well as the 
change in grade severity (P = 0.004).
 Age at diagnosis and age at first visit were both significant risk 
factors for changes in sum (Beta -0.649, P = 0.007, Beta 0.642, 
P = 0.028, respectively). The number of years after completion 
of therapy showed marginal effects on the change in sum of LEs 
(Beta -0.423, P = 0.056). When analyzed by diagnostic groups, 
brain tumor and lymphoma were significant factors for sum (all 
P = 0.001). Among treatment modalities, only radiotherapy was 
a significant factor affecting sum (P = 0.001). Wilms tumor was 
the only diagnosis to have favorable changes in the severity and 
sum, but the effects were not significant (Beta -0.030, P = 0.773; 
Beta -0.105, P = 0.346, respectively).
DISCUSSION
Although LEs in cancer survivors are a well-known health is-
sue, comprehensive follow-up data are limited. Survivors who 
actively participate in an LTFC follow-up usually expect to be 
monitored to allow for early detection of complications and 
cancer recurrences (17). However, comprehensive long-term 
follow-up is frequently difficult to perform because of limited 
local resources and expertise. It has been shown that there is a 
discrepancy between patient self-reports, medical records, and 
findings on clinical examinations (8, 18).
 Our present study was based on 2008 to 2011 follow-up data 
from an LTFC which opened in 2005. The LTFC provided survi-
vors with continuous and detailed consulting regarding their 
health, and each patient was examined by an oncologist to as-
sess LEs. As a result, the participation rate in our study was 
high—about 80%--from our initial report. Survivor participa-
tion rate is primarily dependent on patient satisfaction with 
Fig. 1. Severity and sum of grades of late effects in childhood cancer survivors by 
demographic and clinical factors. (A) Demographics and treatment factors, (B) Diag-
nosis. *Significantly different between initial and recent follow-up data (P < 0.05). 
HSCT, hematopoietic stem cell transplantation; NB, neuroblastoma; RT, radiotherapy; 
WT, Wilms tumor. 
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Fig. 2. Number, severity and sum of grades of late effects in childhood cancer survi-
vors by age. (A) Age at diagnosis (yr), (B) Age at initial visit (yr), (C) Years after treat-
ment completion (yr). Number, severity and sum of grades in each age group were all 
significantly different between initial and follow-up visits. *Data significantly different 
between two recent visits for each age group (using analysis of variance and post hoc 
testing by least significant difference [P < 0.05]).
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consulting at an LTFC, and most studies report that over 50% of 
survivors are lost to follow-up (19-21). High participation rate 
in this study, along with consulting for survivors’ health issues 
and detailed examination of factors affecting LEs are main 
strengths of our study.
 Most of the survivors experienced additional LEs or had an 
exacerbation of existing LEs during follow-up. The percentage 
of survivors with LEs increased from 59.8% at initial visit to 75.1% 
at final visit. The percentages were similar to other reports: 62.4% 
in the United States and 74.5% in the Netherlands (2, 8). Increase 
in the number of LEs can mainly be attributed to survivors’ heal-
th conditions and follow-up duration. However, selection bias 
is also a factor. Some survivors refused to participate in the LTFC 
despite recommendations for LTFC. Although risk factors (e.g., 
diagnosis and treatment modality) in non-responders were not 
significantly different than responders, non-responders were 
older at initial visit than responders. Non-responders also had 
more time elapsed since the completion of treatment. The mean 
age at initial visit was 17.4 yr and more than 12.1 yr had passed 
since they completed their treatment. As these patients grew 
older and more time passed since completion, the concern or 
worry about cancer recurrence or LEs lessened (22). In addi-
tion, adult survivors can independently decide whether to par-
ticipate in an LTFC follow-up unlike younger survivors for whom 
parents play a vital role in caring and monitoring (23).
 The number and severity of LEs at initial visit were lower in 
non-responders than in responders. Non-responders could 
have been in better general health than other survivors, leading 
to low participation rate and selection bias (22). According to 
data from the Childhood Cancer Survivor Study (CCSS), survi-
vors who were followed were significantly more likely to have a 
chronic health condition compared to those not participating 
(69.1% in LTFU clinic vs 48.7% with no follow-up) (22). Another 
reason survivors refuse participate may be to avoid additional 
emotional trauma by discussing childhood cancer experiences 
(24). Despite these potential biases, it is important to empha-
size that most survivors who were followed at the LTFC showed 
an increase in the number and severity of LEs. This finding is 
consistent with other studies on changes of LEs during follow-
up (2, 25). Thus, regular follow-up at an LTFC is recommended 
not only for survivors at risk but also for those who have entered 
adulthood and are relatively healthier than other survivors.
 Both the percentage of patients with LEs and the mean se-
verity of LEs increased during the follow-up for most of the body 
systems. Particularly, endocrine (including growth or sexual/
pubertal effects), musculoskeletal, and neurologic abnormali-
ties became more frequent and severe. Endocrine abnormali-
ties are the most common LEs likely, because survivors of child-
hood cancers were in the stage of active growth and develop-
ment of second sexual characteristics during treatment for can-
cers (2, 8, 11, 26).
 Our study found that the number, mean severity, and sum of 
LEs all were increased, regardless of most clinical factors. The 
number of LEs, mean severity, and sum were the highest in 
brain tumor survivors and the lowest among Wilms tumor sur-
vivors. These findings were consistent with previous reports (2, 
10, 11, 27). On the other hands, it is striking that the risk of death 
was still higher among these survivors than the general popula-
tion when they were followed continuously (28). Therefore, 
survivors of Wilms tumor should also undergo comprehensive 
follow-up at an LTFC.
 Lymphoma was also found to be a significant factor for change 
in the sum and the number of LEs by multivariate analysis. It 
has been previously reported that lymphoma is a risk factor for 
developing cardiovascular LEs, secondary cancers or pulmo-
nary abnormalities (29).
 In general, the number, severity and sum of LEs increased by 
age at diagnosis, age at initial visit, and years since completion 
of treatment. This means that care at an LTFC should be pro-
vided to most of survivors, regardless of age. It should also be 
Table 4. Multivariate analysis on the change in sum of grades, number, and severity of late effects
Clinical factor
Change in number Change in severity Change in sum
Beta P value Beta P value Beta P value
Sex 0.044 0.535 0.011 0.876 0.034 0.622 
Age Age at diagnosis*
Age at the first visit*
Year after completion*
-0.452 
0.475 
-0.329 
0.067 
0.109 
0.144 
-0.036 
-0.118 
0.182 
0.888 
0.705 
0.443 
-0.649 
0.642 
-0.423 
0.007 
0.028 
0.056 
Diagnosis Brain tumor†
Wilms tumor
Lymphoma†
Neuroblastoma
Other tumors
0.246 
0.059 
0.327 
0.141 
0.137 
0.010 
0.578 
0.000 
0.110 
0.175 
0.001 
-0.105 
0.128 
0.056 
0.077 
0.993 
0.346 
0.180 
0.548 
0.468 
0.325 
-0.030 
0.292 
0.082 
0.101 
0.001 
0.773 
0.001 
0.343 
0.309 
Treatment Chemotherapy
HSCT
Radiotherapy‡
Surgery
0.009 
-0.071 
0.281 
-0.034 
0.906 
0.348 
0.001 
0.735 
-0.075 
-0.072 
0.246 
-0.019 
0.343 
0.365 
0.004 
0.856 
0.002 
0.000 
0.265 
0.026 
0.978 
1.000 
0.001 
0.792 
*Statistically significant for change in sum (P < 0.05); †Statistically significant for change of sum and number (P < 0.05); ‡Statistically significant for change of sum, number, 
and severity (P < 0.01). GI, gastrointestinal; HSCT, hematopoietic stem cell transplantation.
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emphasized that LEs related to development involving endo-
crine, musculoskeletal, and neurologic systems are most likely 
to occur. Therefore, adolescents and young adult survivors should 
be carefully followed.
 For the change in sum, all age groups were significant in multi-
variate analysis. Patients of younger age at the time of diagnosis 
were at greater risk of showing adverse changes in LEs during 
follow-up (Beta -0.649, P = 0.007). Older age at the first visit to 
the LTFC was found to be a risk of developing LEs in the future 
(Beta 0.642, P = 0.028). Although the significance was marginal, 
the risk of developing LEs decreased as survivors aged and more 
time passed since completing treatment (Beta -0.423, P = 0.056). 
According to these findings, survivors diagnosed at young age 
should be regularly and frequently followed. If survivors’ first 
visits are at an older age, they should initially be examined more 
frequently. The first visit at older age implies that survivors might 
have lost the opportunity for early LE detection and timely treat-
ment.
 Cancer survivorship program is the emerging field in oncol-
ogy. In the Western countries, the survivorship care protocols 
have been published and used. Many cancer centers have long-
term follow-up clinics for childhood cancer survivors (30). In 
Asia-Pacific regions including Korea, the survivorship programs 
are under development. We published the first comprehensive 
report on the childhood cancer survivors in Korea in 2009 and 
the nationwide study activities for cancer survivors just have 
started (11, 30, 31).
 Our study has some unique points. Late effects in survivors 
were confirmed in person by oncologists, and the cohort was 
comprehensively followed for 3 yr. We could also characterize 
non-responders to follow-up at the LTFC. Finally, this follow-
up report is the first evaluating patients in Asia; similar data are 
still insufficient worldwide. A major limitation of this study is 
the small sample size. We tried to overcome this limitation by 
performing comprehensive follow-ups of the survivors.
 In conclusion, LEs are common in childhood cancer survi-
vors. Regardless of most clinical risk factors, the number and 
severity of LEs tend to increase over time. Survivors of child-
hood cancer need careful and comprehensive follow-up in or-
der to identify and manage LEs.
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Table S1. Categorization of late effects by organ or system
Involved system Specific late effects*
Bone marrow Anemia, polycythemia, leukopenia, marrow hypocellularity, neutropenia, thrombocytopenia, thrombocytosis, others
Skin Alopecia, atrophy, fibrosis, nail changes, vitiligo, other
Obesity Obesity (based on body mass index), others
Ear Hearing loss, otitis externa, otitis media, tinnitus, others
Eye Cataract, dry eye syndrome, glaucoma, retinopathy, uveitis, vitreous hemorrhage, others
Cardio-vascular Cardiac arrhythmia, cardiomyopathy, congestive heart failure, hypertension, hypotension, ventricular dysfunction, others
Lung Paranasal sinus infection, pneumonitis, pulmonary dysfunction, pulmonary fibrosis, others
Gastro-intestinal Bowel obstruction, colitis, dental abnormalities, chronic enterocolitis, constipation, fecal incontinence, hepatic dysfunction, ileus, malabsorption,  
  mucositis, others
Kidney Hematuria, hemorrhagic cystitis, incontinence, proteinuria, renal insufficiency, renal tubular disorder, others
Neurologic Ataxia, cerebrovascular ischemia, cognitive disturbance, dizziness, hydrocephalus, leukoencephalopathy, memory impairment, mood alteration,  
  neuropathy (cranial, motor, or sensory), phrenic nerve dysfunction, seizures, speech impairment, tremor, others
Musculo-skeletal Fracture, limb discrepancy, musculoskeletal hypoplasia, osteonecrosis, osteopenia, osteoporosis, scoliosis, others
Thyroid Hyperthyroidism, hypothyroidism, thyroid nodule, others
Growth Growth deceleration, growth hormone deficiency, short stature, others
Sexual/Puberty Delayed puberty, gonadotophin secretion abnormality, gynecomastia, primary gonadal failure, premature menopause, infertility, irregular menses,  
  precocious puberty, others
Metabolic Adrenal insufficiency, dyslipidemia, glucose intolerance, hypocalcemia, hypercalcemia, others
*Late effects were expressed using the terminology based on the Common Terminology Criteria of Adverse Events version 3.0 (CTCAE v3.0). Adverse events confirmed two 
years after completion of cancer therapy were regarded as late effects rather than acute treatment toxicities. Evaluation methods were selected based on the risks and individu-
alized follow-up schedules, which were determined according to the treatment history of the survivor. For all categories, history and physical examination were included. For 
each late effect, evaluations were repeated with appropriate follow-up intervals. 
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Table S3. Differences in distribution of late effects at initial visit between responders 
and non-responders
Initial late effects
P valueNon-responders 
(n = 48)
Responders
(n = 193)
Total sum of grade 1.0 ± 0.2 1.7 ± 0.1 0.010
Presence No
Yes
26 (54.2%)
22 (45.8%)
71 (36.8%)
122 (63.2%)
0.028
Number 1
2
3
4
5
13 (27.1%)
7 (14.6%)
1 (2.1%)
1 (2.1%)
0 (0.0%)
71 (36.8%)
30 (15.5%)
13 (6.7%)
7 (3.6%)
1 (0.5%)
0.048
Severity Mild
Moderate
Severe
Life-threatening
12 (25.0%)
7 (14.6%)
3 (6.3%)
0 (0%)
49 (25.4%)
50 (25.9%)
22 (11.4%)
1 (0.5%)
0.016
Table S2. Demographic characteristics of followed survivors and lost-to-follow-up survivors
Characteristic Non-respondents (n = 48) Respondents (n = 193) P value
Sex
Male
Female
30 (62.5%)
18 (37.5%)
120 (62.2%)
73 (37.8%)
0.967
Age at diagnosis, yr (median, range) 5.0 (0.2-16.8) 4.4 (0.0-16.8) 0.628
Age at initial visit, yr (median, range) 17.4 (4.1-33.7) 13.1 (2.6-28.9) 0.001
Current age, yr (median, range) 20.6 (7.3-36.8) 16.2 (5.7-26.2) 0.001
Time after completion (median, range) 12.1 (5.5-21.9) 9.0 (5.1-24.7) < 0.001
Diagnosis
Leukemia
Lymphoma
Wilms tumor
Brain tumor
Neuroblastoma
Others†
24 (50.0%)
5 (10.4%)
4 (8.3%)
4 (8.3%)
3 (6.3%)
8 (16.7%)
71 (36.8%)
30 (15.5%)
19 (9.8%)
21 (10.9%)
10 (5.2%)
42 (21.8%)
0.655
Treatment modalities
Chemotherapy only ± surgery
Radiotherapy only ± surgery
Chemotherapy and radiotherapy
Surgery only
26 (54.2%)
0 (0%)
18 (37.5%)
4 (8.3%)
115 (59.6%)
1 (0.5%)
74 (38.3%)
3 (1.6%)
0.088
Type of chemotherapy (n = 233, 96.7%)
Alkylating agents and others
Anthracycline agents and others
Anthracyclines and alkylating agents
Others 
44/48 (91.7%)
7 (14.6%)
2 (4.2%)
18 (37.5%)
21 (43.8%)
189/193 (97.9%)
42(21.8%)
19 (9.8%)
85 (44.0%)
47 (24.4%)
0.030
0.048
Type of radiotherapy (n = 93, 38.6%)
Head, neck and spine
Chest
Abdominopelvic
TBI
Others
18/48 (37.5%)
15 (75%)
0 (0%)
2 (10.0%)
0 (0%)
3 (15.0%)
75/118 (38.9%)
50 (58.8%)
5 (5.9%)
17 (20.0%)
6 (71%)
7(8.3%)
0.862
0.419
Type of surgery (n = 96, 39.8%)
Kidney
Brain
Abdomen (liver, adrenal gland)
Gonad
GI
Others
16/32 (33.3%)
3 (18.8%)
3 (18.8%)
1 (6.3%)
2 (12.5%)
0 (0%)
7 (43.8%)
80/193 (41.5%)
13 (13.5%)
24 (30.0%)
13 (13.5%)
7 (8.8%)
5 (5.2%)
19 (23.8%)
0.304
0.549
Type of HSCT (n = 42, 17.4%)
Autologous
Allogeneic
2/46 (4.2%)
1 (50.0%)
1 (50.0%)
40/193 (20.7%)
19 (47.5%)
21 (52.5%)
0.007
0.945
*Percentage is based on all survivors (n = 241); †Others include 17 Langerhans cell histiocytosis (systemic type), 10 abdominopelvic germ cell tumor, 8 hepatoblastoma, 5 
rhabmomyosarcoma, 2 leiomyosarcoma, 2 eosinophilic granuloma, 2 adrenocortical carcinoma, 1 Ewing sarcoma, 1 rhabdoid tumor of the neck, 1 mediastinal teratoma, and 1 
malignant myofibroblastic tumor. GI, gastrointestinal; HSCT, hematopoietic stem cell transplantation; TBI, total body irradiation. 
